Tenax Therapeutics Phase 3 trial of TNX-103 misses primary endpoint

August 10, 2026 7:00 AM

Tenax Therapeutics, Inc. (Nasdaq: TENX) announced topline results from its Phase 3 LEVEL clinical trial evaluating TNX-103, an oral form ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found